CVS Health (NYSE:CVS) Upgraded to “Outperform” at Leerink Partners

CVS Health (NYSE:CVS) was upgraded by research analysts at Leerink Partners from a “market perform” rating to an “outperform” rating in a research note issued to investors on Thursday,Briefing.com Automated Import reports. The firm presently has a $75.00 target price on the pharmacy operator’s stock, up from their prior target price of $55.00. Leerink Partners’ price target indicates a potential upside of 18.61% from the company’s current price.

Several other research firms have also recently weighed in on CVS. Wolfe Research upped their price target on shares of CVS Health from 67.00 to 70.00 and gave the company an “overweight” rating in a report on Tuesday. Piper Sandler dropped their target price on CVS Health from $72.00 to $64.00 and set an “overweight” rating on the stock in a report on Monday, November 25th. Truist Financial dropped their price objective on CVS Health from $67.00 to $60.00 and set a “buy” rating on the stock in a research note on Monday, January 6th. Barclays lowered their target price on shares of CVS Health from $75.00 to $71.00 and set an “overweight” rating on the stock in a report on Thursday, November 7th. Finally, Deutsche Bank Aktiengesellschaft upgraded shares of CVS Health from a “hold” rating to a “buy” rating and set a $66.00 price target for the company in a research note on Tuesday, December 3rd. One analyst has rated the stock with a sell rating, four have issued a hold rating and seventeen have given a buy rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $68.89.

CVS Health Trading Up 15.0 %

CVS opened at $63.23 on Thursday. CVS Health has a fifty-two week low of $43.56 and a fifty-two week high of $80.75. The company has a market cap of $79.57 billion, a price-to-earnings ratio of 16.05, a price-to-earnings-growth ratio of 0.60 and a beta of 0.61. The company has a debt-to-equity ratio of 0.80, a current ratio of 0.80 and a quick ratio of 0.59. The firm has a 50 day simple moving average of $50.61 and a 200 day simple moving average of $55.92.

CVS Health (NYSE:CVS) last released its quarterly earnings data on Wednesday, February 12th. The pharmacy operator reported $1.19 EPS for the quarter, beating analysts’ consensus estimates of $0.89 by $0.30. CVS Health had a return on equity of 10.72% and a net margin of 1.36%. On average, sell-side analysts anticipate that CVS Health will post 5.14 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the company. Aviva PLC grew its holdings in CVS Health by 154.9% during the 4th quarter. Aviva PLC now owns 681,209 shares of the pharmacy operator’s stock worth $30,579,000 after acquiring an additional 414,008 shares during the last quarter. Dynamic Technology Lab Private Ltd acquired a new position in shares of CVS Health during the fourth quarter worth $1,111,000. Rhenman & Partners Asset Management AB increased its holdings in CVS Health by 45.4% in the fourth quarter. Rhenman & Partners Asset Management AB now owns 267,500 shares of the pharmacy operator’s stock valued at $12,008,000 after purchasing an additional 83,500 shares during the period. Resona Asset Management Co. Ltd. bought a new position in CVS Health during the 4th quarter worth $19,185,000. Finally, Integrated Quantitative Investments LLC acquired a new position in shares of CVS Health in the fourth quarter worth approximately $426,000. Institutional investors and hedge funds own 80.66% of the company’s stock.

CVS Health Company Profile

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.